⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ANAB News
AnaptysBio, Inc. Common Stock
Form 8-K
sec.gov
ANAB
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
globenewswire.com
ANAB
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
globenewswire.com
TRAX
ANAB
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
globenewswire.com
ANAB
Form 8-K
sec.gov
ANAB
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
ANAB
VNDA
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
prnewswire.com
VNDA
ANAB
Anaptys Announces Participation at Upcoming Investor Conferences
globenewswire.com
ANAB
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
globenewswire.com
ANAB
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ANAB